NovaDel Reports First Quarter 2004 Progress

NovaDel Reports First Quarter 2004 Progress 


FLEMINGTON, N.J., Apr. 7  /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. 
(BULLETIN BOARD: NVDL)  reported substantial progress in product development and
commercial activities during thecalendar quarter ended March 31, 2004.

Cash at Jan. 31, 2004, the company's latest official reporting period, stood at
$12.8 million compared to $3.0 million in the year ago period, due to proceeds
from a private offering of the company's common shares completed earlier in
January. Net operating loss for the Jan. 31 period just ended was on budget at
$1.4 million, or 6 cents per share, compared to a loss of $1.8 million, or 12
cents per share, in 2003's first quarter.

"Our strengthened financial position is enabling us to move forward aggressively
with our portfolio development programs and to make a timely filing for our
first new product, lingual spray nitroglycerin," said Gary Shangold, MD, CEO of
NovaDel.

NovaDel is currently readying four Tier One product candidates for pilot testing
with its patented lingual spray drug delivery technology.

These include lingual spray versions of Zofran(R) (ondansetron), the leading
anti-emetic marketed in the US by GlaxoSmithKline, Imitrex(R) (sumatriptan) also
marketed in the US by GlaxoSmithKline, Ambien(R) (zolpidem) marketed in the US
by Sanofi, and Xanax(R) (alprazolam), which is sold by Pfizer and several
generic producers.

The studies will confirm the utility of NovaDel's patented lingual spray
technology to provide rapid therapeutic blood levels of the test compound, while
avoiding the GI route of administration and first-pass liver effects. These
features are inherent in NovaDel's patented method of drug delivery which allows
drugs to enter the blood stream directly through the oral mucosa lining the
mouth.

A New Drug Application (NDA) for the company's first planned product,
nitroglycerin, is expected to be filed by the end of June.

Dr. Shangold said the company is very pleased with the progress of early
discussions with potential marketing partners interested in funding further
development and commercialization of several Tier One product candidates.

About NovaDel Pharma Inc.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and over-the-
counter drugs.  The Company's proprietary lingual spray technology delivery
system offers the patient (i) fast onset of action; (ii) improved drug safety by
reducing the required drug dosage and reducing side effects; (iii) improved
patient convenience and compliance; and (iv) enhanced dosage reliability.  The
Company plans to develop such products independently and through collaborative
arrangements with major pharmaceutical and biotech companies.

Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known andunknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain
approval for products under development. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration Statements,
filed with the Securities and Exchange Commission.  In assessing forward-looking
statements contained herein, if any, the reader is urged to carefully read all
cautionary statements contained in such filings.

   CONTACT:  Barry C. Cohen
             VP Business & New Product Development
          908-782-3431, ext. 2160
             NovaDel Pharma Inc.

             Thomas Redington
             [phone]
             [phone]
             

DATASOURCE: NovaDel Pharma Inc.



CONTACT:  Barry C. Cohen, VP Business & New Product Development, NovaDel

Pharma Inc., [phone], ext. 2160; Thomas Redington, [phone], or

[phone], , for NovaDel Pharma Inc.

Copyright